There are currently 1308 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Healthcare of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Advanced Cancer
Register for Updates
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Emory Winship Cancer Institute, Atlanta, Georgia
Conditions: Acute Myeloid Leukemias
Register for Updates
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Gender:
ALL
Ages:
Between 3 years and 10 years
Trial Updated:
03/26/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Achondroplasia
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Neumora Investigator Site, Atlanta, Georgia
Conditions: Major Depressive Disorder
Register for Updates
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. These types of study drugs are collectively known as immune checkpoint inhibitors. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Emory Healthcare, Emory Clinic, Atlanta, Georgia
Conditions: Melanoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
NCT06750276
Recruiting
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Liver Fibrosis, Hepatic Cirrhosis
Register for Updates
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT05629208
Recruiting
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Cutaneous Lupus Erythematosus (CLE)
Register for Updates
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/25/2025
Locations: Emory University School of Medicine - Atlanta- Site Number : 8400020, Atlanta, Georgia
Conditions: Chronic Graft Versus Host Disease
Register for Updates
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241
Recruiting
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
03/25/2025
Locations: Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/25/2025
Locations: Research Site, Atlanta, Georgia +1 locations
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
NCT05987332
Recruiting
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Northside Hospital Atlanta, Atlanta, Georgia
Conditions: Metastatic Uveal Melanoma
Register for Updates